<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="HB4B608345857454AB44543E653A988FE" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>113 HR 5748 IH: The Medicaid Generic Drug Price Fairness Act of 2014</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2014-11-20</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>2d Session</session>
		<legis-num>H. R. 5748</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20141120">November 20, 2014</action-date>
			<action-desc><sponsor name-id="C000984">Mr. Cummings</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To extend the requirement that drug manufacturers that increase prices faster than inflation pay an
			 additional rebate to State Medicaid programs to include manufacturers of
			 generic drugs.</official-title>
	</form>
	<legis-body id="H7D238876849F4C3FBBA5B4C545BFEED2" style="OLC">
		<section id="HFD38978DDBC640EA84FA3CD8AA56D8D6" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>The Medicaid Generic Drug Price Fairness Act of 2014</short-title></quote>.</text>
		</section><section id="H2D0E8E67C66C4C51AE9E88A77DFF341B"><enum>2.</enum><header>Applying the medicaid additional rebate requirement to manufacturers of generic drugs</header>
			<subsection id="HF946F6CB672E49A38DD0A1868226E189"><enum>(a)</enum><header>In general</header><text>Section 1927(c)(3)(A) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396r-8">42 U.S.C. 1396r–8(c)(3)(A)</external-xref>) is amended—</text>
				<paragraph id="HE73AFE443F5F4CAD8F5C61A169E8E7BE"><enum>(1)</enum><text>in clause (ii), by striking the period and inserting <quote>,</quote>; and</text>
				</paragraph><paragraph id="HE598F765D5464575A50F6EBC70475ABB"><enum>(2)</enum><text>by adding at the end the following flush text: <quote>and shall be increased by an amount determined in the same manner as the increase in the amount of
			 a rebate for a single source drug or an innovator multiple source drug is
			 determined under paragraph (2).</quote>.</text>
				</paragraph></subsection><subsection id="H55083C02081147B0BB3AC945C7458600"><enum>(b)</enum><header>Effective date</header><text>The amendments made by this section shall apply to rebate periods beginning on or after the date of
			 enactment of this Act.</text>
			</subsection></section></legis-body>
</bill>


